Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.82 USD | +5.20% | +0.55% | +131.85% |
Feb. 21 | Neurosense Therapeutics Ltd. Reports Additional Positive Results from Its ALS Phase 2B Paradigm Trial | CI |
Dec. 28 | NeuroSense Gets Non-Compliance Notice From Nasdaq | MT |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
- Stock
- Equities
- Stock NeuroSense Therapeutics Ltd. - Nasdaq
- Revisions NeuroSense Therapeutics Ltd.